Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCapital Bluecross Allergy Testing Coverage Update …
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy MP 2.001

    Allergy Testing and Immunotherapy

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.001 alerts

    Get alerted when Policy MP 2.001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, quantity limits, investigational status, coding, and prior authorization requirements for allergy diagnostic testing and immunotherapy services for Capital Bluecross members and applicable products; affects providers ordering or administering allergy tests and immunotherapy.

    Policy Summary
    PayerCapital Bluecross
    PolicyAllergy Testing and Immunotherapy
    Policy CodePolicy MP 2.001
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewFeb 19, 2026
    Next Review DateJul 21, 2026
    Key ActionEnsure testing and immunotherapy meet medical necessity: attempt conservative therapy first and document symptoms, correlation to history/exposure, and periodic re-evaluations every 6–12 months with evidence of benefit.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    70percutaneous test limit
    40intracutaneous test limit
    80SET endpoint limit
    1 yrmaintenance NMN after
    6-12 more-eval interval
    86807/86808recent code removals

    Coverage Criteria for Allergy Testing and Immunotherapy

    inv-01: Allergy Testing — Medically Necessary

    Considered medically necessary when ALL of the following are met:

    Primary criteria: Symptoms are not adequately controlled by empiric conservative therapy; testing must correlate specifically to the individual's history, risk of exposure and physical findings; and test technique and/or allergens tested must have proven efficacy demonstrated through scientifically valid studies published in the peer-review literature.

    From policy introductory criteria

    Permitted test types: Direct skin test (percutaneous/scratch/prick/puncture or intracutaneous/intradermal), patch test (application test), photo patch test, bronchial challenge test, oral food challenge (open, single blind, or double blind), serial endpoint testing (SET/SDET/IDT) when used with immunotherapy.A cumulative total of 70 percutaneous or 40 intracutaneous tests per benefit period; a cumulative total of 80 endpoints (SET, SDET, IDT) per benefit period. Quantity level limits greater than these amounts will be considered not medically necessary per benefit period.

    Specific technique list and quantity limits

    inv-02: Repeat Skin Testing — Medically Necessary

    Repeat skin testing may be considered medically necessary in the following situations:

    Pediatrics: Children initially sensitive to food or indoor environmental exposures who later develop pollen and outdoor mold sensitivities.

    Repeat testing justified for new sensitizations in children

    Adults who require reevaluation: those with food allergy needing assessment for resolution; those who have received 3–5 years of venom immunotherapy requiring reevaluation for resolution of venom allergy; or adults who develop increased atopic symptoms suggesting new sensitizations.

    Adult repeat-testing indications

    inv-03: Allergy Immunotherapy — Medically Necessary

    Considered medically necessary when ALL of the following are met:

    Indication: Individual has demonstrated hypersensitivity that cannot be managed by medication, avoidance, or environmental control measures. Injections of airborne or insect venom allergens should be prepared individually for the member.

    Immunotherapy prepared individually for airborne or insect venom allergens

    Maintenance monitoring: Individuals must be re-evaluated every 6 to 12 months while receiving allergy immunotherapy to determine efficacy, need for dosing or allergen content adjustments, ensure compliance, and monitor for local and systemic adverse reactions.Continuation beyond one year of maintenance requires documentation of benefit (noticeable decrease of symptoms, increased tolerance to offending allergen, reduction in medication usage) or a reasonable explanation for lack of improvement.

    Continuation requires documented benefit after one year

    inv-04: Covered Services When Medically Necessary

    Covered when medically necessary for appropriate diagnosis and management of listed allergic conditions and when supported by member benefits.

    General coverage condition: Procedure codes listed as 'Covered when Medically Necessary' are covered only when the service meets medical necessity and the member has benefit eligibility on the date of service; identification of a code in the coding section does not by itself denote coverage.

    Coverage determination is based on medical necessity and benefit terms.

    Other allergy tests and immunotherapy approaches are considered investigational due to insufficient evidence to support their use. Examples specifically listed in the policy include the nasal challenge test and the conjunctival (ophthalmic mucous membrane) challenge test, which are described as primarily research tools with limited established clinical utility, and at‑home administration of allergy immunotherapy (including preparation of serum and related services), which is considered investigational except in rare, individualized circumstances.

    Procedure code S9338 is designated as investigational and therefore not covered under this policy; submission or use of this code may result in claim denial.

    Procedure codes and policy statements that have been identified as managed by an external vendor have been removed from the payer's direct coverage statements. These vendor‑managed procedures are to be managed through the vendor's authorization and billing processes rather than through direct payer coverage statements.

    Quantity level limits (QLLs) are applied to in vivo testing. A cumulative total of > 70 percutaneous (scratch/prick/puncture) tests or > 40 intracutaneous/intradermal tests per benefit period will be considered not medically necessary. Similarly, a cumulative total exceeding 80 Serial Endpoint/Test endpoints (SET, SDET, IDT) per benefit period will be considered not medically necessary.

    Services that are determined to be not medically necessary or that are not included in a member's specific benefit program may be denied. The identification of a billing code in the coding section does not guarantee coverage; coverage is contingent on the member's benefit terms, eligibility on the date of service, and documentation that the service meets medical necessity criteria.

    Coding: Procedure and Diagnosis Codes

    Investigational / Not Covered Procedure CodesHCPCSNot Covered
    S9338Procedure Code S9338 (investigational and therefore not covered)
    Covered when Medically Necessary Procedure CodesCPTCovered
    95004
    95017
    95018
    95024
    95027
    95028
    95044
    95052
    95056
    95070
    1–10 of 31
    1/4
    ICD-10-CM Diagnosis Codes and Z codesICD-10
    B44.81Allergic bronchopulmonary aspergillosis
    D82.0Wiskott-Aldrich syndrome
    H65.411Chronic allergic otitis media, right
    H65.412Chronic allergic otitis media, left
    H65.413Chronic allergic otitis media, bilateral
    J30.0Vasomotor rhinitis
    J30.1Allergic rhinitis due to pollen
    J30.2Other seasonal allergic rhinitis
    J30.81Allergic rhinitis due to animal (cat) (dog) hair and dander
    J30.89Other allergic rhinitis
    1–10 of 161
    1/17
    Policy coding changes and notable codesCPT
    0165Unew code added (per 04/01/2020 update)
    0178Unew code added (per 05/29/2020 update)
    95071deleted (per 01/28/2021 update)
    86807procedure code removed (not applicable) effective 07/21/2025
    86808procedure code removed (not applicable) effective 07/21/2025
    ICD-10 code updatesICD-10
    L24A9ICD-10 code added (09/01/2021 administrative update)
    L24A0ICD-10 code added (09/01/2021 administrative update)
    Z91.014ICD-10 code added (09/01/2021 administrative update)
    R05.1ICD-10 code range added (09/01/2021 administrative update)
    R05.9ICD-10 code range added (09/01/2021 administrative update)
    C90.0ICD-10 code removed (09/30/2022)
    inv-15: Skin prick/antigen screening — screening and antigen survey limits and contextual rules.
    Screening limitScreen with no more than 14 relevant antigens plus appropriate controls.
    Antigen survey when immunotherapy contemplatedIf screening is positive and immunotherapy is contemplated, use no more than 40 antigens (more may be justified in special circumstances).
    Routine IDT quantification guidanceUse no more than 80 intradermal dilutional (IDT) tests routinely; more extensive testing may be justified in special circumstances.
    Contextual rule — relation to immunotherapyAntigen survey expansion to 40 is specifically when immunotherapy is being considered to identify relevant allergens for treatment planning.

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Confirm product-specific benefit rules before ordering

    This policy applies only to specified Capital Blue Cross products and programs; benefit rules vary by product (for example, FEP PPO follows the FEP Medical Policy Manual, and CHIP/Capital Cares 4Kids is exempt from the quantity level limits). Confirm the member’s product and follow any product‑specific prior authorization or benefit direction before ordering or billing.

    • FEP PPO: refer to the FEP Medical Policy Manual (link in policy).
    • CHIP (Capital Cares 4Kids): quantity level limits do not apply.
    Prior Authorization

    Verify medical necessity and member benefits for listed codes

    Ensure listed allergy testing and immunotherapy procedure codes are performed only when medically necessary and covered by the member’s benefit; verify eligibility and medical necessity prior to billing and, if required, obtain prior authorization per plan rules.

    • Coverage is contingent on medical necessity and member benefit eligibility on the date of service.

    Background and Scope

    Allergic disorders produce a range of localized or systemic reactions and may be acute or chronic. Allergy testing includes in vivo methods — such as percutaneous (skin prick/scratch), intracutaneous/intradermal, patch, photo patch, bronchial challenge, and oral food challenge (open, single‑blind, or double‑blind) — and in vitro IgE analyses. Serial Endpoint Testing (SET) is an intradermal technique using increasing antigen doses to identify an endpoint dilution and may be used to guide initiation of immunotherapy. The policy scope covers diagnostic testing and immunotherapy services, the required documentation standards, applicable quantity limits, and investigational exclusions for Capital Bluecross benefit programs.

    Definitions

    inv-35: Allergen — definition and examples.
    DefinitionAny substance that causes a hypersensitivity reaction (examples include inhalants, foods, drugs, infectious agents, contactants, and physical agents).
    Common examples — inhalantsDusts, pollens, fungi, smoke, perfumes, and odors of plastics.
    Common examples — foods and drugsFoods: wheat, eggs, milk, chocolate, strawberries; Drugs: aspirin, antibiotics, serums.
    Other examplesInfectious agents (bacteria, viruses, fungi), contactants (chemicals, animals, plants, metals), and physical agents (heat, cold, light, pressure).
    inv-36: Allergy — definition of immune response and clinical spectrum.
    DefinitionAn immune response to a foreign antigen that results in inflammation and organ dysfunction.

    Policy Revision History and Notes

    Policy Summary
    PayerCapital Bluecross
    PolicyAllergy Testing and Immunotherapy
    Policy CodePolicy MP 2.001
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewFeb 19, 2026
    Next Review DateJul 21, 2026
    Key ActionEnsure testing and immunotherapy meet medical necessity: attempt conservative therapy first and document symptoms, correlation to history/exposure, and periodic re-evaluations every 6–12 months with evidence of benefit.
    SourceLink
    On This Page
    Coverage Criteria for Allergy Testing and ImmunotherapyCoding: Procedure and Diagnosis CodesProvider Actions, Authorization, and DocumentationBackground and ScopeDefinitionsPolicy Revision History and Notes
    inv-16: Percutaneous test limit — Cumulative total of 70 per benefit period.
    Percutaneous test cumulative limitA cumulative total of seventy (70) percutaneous (scratch, prick, or puncture) tests may be considered medically necessary per benefit period.
    Not medically necessary thresholdQuantity level limits greater than seventy percutaneous tests per benefit period will be considered not medically necessary.
    Applicable techniquesApplies to percutaneous direct skin testing used for diagnosis, evaluation, and treatment of allergies (e.g., inhalants, foods, venoms).
    inv-17: Intracutaneous/intradermal test limit — Cumulative total of 40 per benefit period.
    Intracutaneous/intradermal cumulative limitA cumulative total of forty (40) intracutaneous (intradermal) tests may be considered medically necessary per benefit period.
    Not medically necessary thresholdQuantity level limits greater than forty intracutaneous tests per benefit period will be considered not medically necessary.
    Scope of useApplies to intracutaneous testing when used for diagnosis, evaluation, and treatment of allergies (e.g., animal, food, pollen, dust mites, mold, insect venoms).
    inv-18: SET/endpoint limit — Cumulative total of 80 endpoint tests per benefit period.
    SET/endpoint cumulative limitA cumulative total of eighty (80) endpoints (SET, SDET, IDT) allergy tests may be considered medically necessary per benefit period.
    Not medically necessary thresholdQuantity level limits greater than eighty endpoint tests per benefit period will be considered not medically necessary.
    Intended clinical useSET is used when performed in conjunction with immunotherapy to determine a safe starting dose for testing or for immunotherapy initiation.
    inv-19: Photo Patch Test contact time — 48 hours.
    Photo Patch Test contact timeThe suspected sensitizer is applied and allowed to remain in contact with the skin for forty-eight (48) hours.
    Procedure sequenceIf no reaction after 48 hours, the site is exposed to ultraviolet light sufficient to produce inflammatory redness; a positive test produces a more severe reaction at the patch site than surrounding skin.
    Clinical purposeUsed to detect contact photosensitization to suspected sensitizers.
  1. Providers must ensure services meet medical necessity and eligibility requirements prior to billing.
  2. Prior Authorization

    Use vendor-managed authorization pathways where indicated

    Follow vendor authorization processes for procedures that the policy identifies as managed by a vendor instead of submitting those procedure requests directly to the payer (policy removed certain procedure codes as not applicable and vendor‑managed per the history).

    • Providers must route authorization/billing for vendor‑managed procedures through the vendor per the 07/21/2025 and 02/19/2026 policy updates.
    • Codes 86807 and 86808 were removed as not applicable and related procedures may be vendor‑managed.
    Step Therapy

    Attempt conservative therapy before testing

    Attempt empiric conservative therapy first; perform allergy testing only when symptoms are not adequately controlled by empiric conservative management and testing will correlate with the patient’s history and exposures.

    • Symptoms must be inadequately controlled by empiric conservative therapy before testing is considered medically necessary.
    • Testing must correlate to the individual’s history, risk of exposure, and physical findings.
    Note

    No action specified

    (Reserved)

    Note

    No action specified

    (Reserved)

    Documentation Required

    Retain documentation demonstrating failure of empiric therapy and correlation to testing or immunotherapy

    Document that symptoms were not controlled by empiric therapy, that testing correlates with the individual’s history/exposure/physical findings, and for immunotherapy document demonstrated hypersensitivity not manageable by avoidance/medication plus re‑evaluations every 6–12 months showing efficacy or a rationale for continuation.

    • Testing documentation: failure of empiric therapy and correlation of test selection to history/exposure and physical findings; test technique/allergens must have proven efficacy.
    • Immunotherapy documentation: demonstrated hypersensitivity not manageable by avoidance/medication; re‑evaluate every 6–12 months with evidence of efficacy, dosing adjustments, compliance, and adverse reaction monitoring.
    Documentation Required

    Confirm eligibility and benefit coverage before billing

    Verify member benefit program and eligibility on the date of service and document medical necessity; payment/coverage are determined by member benefits and medical necessity and claims may be denied if services are not covered under the member’s program or are not medically necessary.

    • Identification of a code in the coding section does not denote coverage; coverage determined by member benefit terms.
    • Confirm eligibility on the date of service and that services meet medical necessity before billing.
    Billing Rule

    Follow current coding tables and vendor instructions

    Use the policy’s updated coding tables and follow vendor instructions noted in the policy history; the policy history documents code additions/removals and administrative updates that affect coding and vendor‑managed procedures.

    • Refer to policy history for code additions/removals (examples: new codes added, deletions, and codes removed effective 07/21/2025).
    • Follow vendor‑managed procedure instructions for codes/statements removed from direct payer management.
    Denial Risk

    Adhere to quantity level limits or risk denial

    Do not exceed the policy’s quantity level limits; requests greater than 70 percutaneous, 40 intracutaneous, or 80 endpoint tests per benefit period will be considered not medically necessary and may be denied.

    • Percutaneous tests: cumulative total up to 70 per benefit period.
    • Intracutaneous/intradermal tests: cumulative total up to 40 per benefit period.
    • Serial endpoint (SET/SDET/IDT) endpoints: cumulative total up to 80 per benefit period.
    Denial Risk

    Document benefit to continue maintenance immunotherapy beyond one year

    For ongoing immunotherapy, re‑evaluate every 6–12 months and discontinue maintenance if no documented clinical benefit after one year in maintenance unless a decrease in symptoms, increased tolerance, reduced medication use, or a reasonable explanation for lack of improvement is documented.

    • Re‑evaluate efficacy, dosing, compliance, and adverse reactions every 6–12 months.
    • Immunotherapy maintenance is considered not medically necessary after one year without documented benefit or justification.
    Denial Risk

    Verify coverage even when codes appear in the policy

    Remember that listing a code in the coding tables does not guarantee coverage; confirm that services are medically necessary and covered by the member’s benefit prior to providing or billing for services.

    • Coverage depends on medical necessity and member benefit eligibility on the date of service.
    • Claims for services that are not medically necessary or not included in the member’s benefit program may be denied.
    Denial Risk

    Avoid use of investigational code S9338

    Do not bill procedure code S9338; it is listed as investigational and not covered and its use may result in denial of payment.

    • Procedure code S9338 is investigational and therefore not covered under this policy.
    Prior Authorization

    Route vendor‑managed procedures through the vendor to avoid denials

    Be aware that removal of procedure codes and statements from the payer policy because they are vendor‑managed may change authorization and billing pathways; route billing/authorizations through the vendor as instructed to avoid denials.

    • Policy updates removed codes/statements that will be managed by the vendor; providers must follow vendor processes rather than billing the payer directly for those procedures.
    • Failure to follow vendor routing may trigger denials.
    Clinical spectrumRanges from life-threatening systemic anaphylaxis and laryngeal edema to milder conditions such as urticaria, hay fever, and rhinitis.
    Mechanism noteAllergic reactions are mediated by antigen–antibody interactions that form the basis of immune responses.
    inv-37: Serial Endpoint Testing (SET) — definition and clinical use (entry 1).
    DefinitionSerial Endpoint Testing (SET) is a form of intradermal skin testing that uses increasing doses of antigen to determine the concentration at which the reaction changes from negative to positive (the endpoint).
    Clinical use — immunotherapySET has been used to guide initiation of immunotherapy by using the endpoint dilution as a safe starting antigen dose.
    Testing methodInvolves serial intradermal injections with increasing antigen concentrations to identify the endpoint reaction.
    inv-38: Bronchial challenge test — description and use.
    PurposeBronchial challenge testing uses histamine or methacholine to determine if the patient has hyper-responsive airways.
    Occupational useVolatile chemicals can be used for bronchial challenge when the suspected allergen is encountered in an occupational setting.
    Clinical indicationUsed to assess airway hyper-responsiveness as part of allergy evaluation when clinically indicated.
    inv-39: Photo Patch Test — definition and 48-hour contact time.
    DefinitionA photo patch test is a contact photosensitization test where the suspected sensitizer is applied to the skin and left in contact for forty-eight (48) hours.
    Procedure after contact timeIf there is no reaction after 48 hours, the area is exposed to ultraviolet light; a positive test produces a more severe reaction at the patch site than surrounding skin.
    Clinical intentUsed to identify photosensitizing contactants causing delayed hypersensitivity reactions.
    inv-40: Serial Endpoint Testing (SET) — definition and clinical use (entry 2).
    Definition (restated)SET is an intradermal testing method using increasing antigen doses to determine the concentration where the reaction changes from negative to positive (endpoint).
    Role in immunotherapyUsed to determine a safe starting dose for immunotherapy by using endpoint dilution as the initial antigen concentration.
    Alternate namesReferred to in policy as SET, SDET, or IDT endpoints when quantifying cumulative endpoint tests.
    inv-41: Home Allergy Immunotherapy — definition and reference to evidence on safety/efficacy.
    DefinitionHome allergy immunotherapy refers to immunotherapy administered in the home setting (home-based subcutaneous or oral immunotherapy protocols).
    Evidence referencesPolicy references surveillance and safety studies (e.g., Epstein et al. AAAAI/ACAAI surveillance; Hurst et al. multicenter prospective study) and clinical statements addressing home SCIT.
    Policy contextHome allergy immunotherapy is discussed in references and clinical care statements; applicability depends on evidence, safety, and program-specific rules.